Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 311 followers
Latest posts
Last updated 1 day ago
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
1 day ago
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in...
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
10 days ago
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in...
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
15 days ago
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete...
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
18 days ago
Susvimo is the first and only continuous delivery treatment that offers an...
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
22 days ago
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
23 days ago
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange...
Change to the Roche Enlarged Corporate Executive Committee
24 days ago
Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
25 days ago
Updated overall survival (OS) results - a key secondary endpoint - reinforce...
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
26 days ago
Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to...
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
about 1 month ago
More than 1 million curable sexually transmitted infections (STIs) are acquired every...
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
about 2 months ago
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease
2 months ago
PADOVA study showed numerical delay in motor progression and positive trends on...